Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Finerenone and serum sodium in patients with heart failure and mildly reduced or preserved ejection fraction: an analysis of FINEARTS-HF

Older observational studies in cirrhosis and heart failure (HF) suggest that treatment with spironolactone is frequently associated with hyponatraemia, which is mechanistically plausible given the known actions of aldosterone. However, the effect of the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Nov 2026

Abstract 13852: Time in Normal-High Potassium Range and Cardiovascular Outcomes in Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Analysis

Background: Serum potassium is a known prognostic marker in patients with heart failure (HF) and chronic kidney disease (CKD), with both hypo- and hyperkalemia associated with adverse outcomes. The POTCAST trial demonstrated that targeting a potassium range of 4.5-5.0 mmol/L may be optimal in patients at high risk f...

Henri Lu, B. Claggett, G. Filippatos et al. · 0 citations
Nov 2026

Abstract 8341: High-Sensitivity C-Reactive Protein, All-Cause Mortality and Heart Failure Hospitalization After Acute Coronary Syndrome in Type 2 Diabetes: Insights from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) Trial

Background: Patients with type 2 diabetes (T2D) remain at high risk for adverse outcomes after acute coronary syndrome (ACS). High-sensitivity C-reactive protein (hsCRP) may identify residual risk in this setting. Objective: To evaluate whether baseline hsCRP is associated with all-cause mortality (ACM) and he...

V. Anagnostopoulou, Guang K. Zhang, N. Girerd et al. · 0 citations
Open access Jul 2026

Prevalence and clinical correlates of metabolic dysfunction-associated steatotic liver disease in heart failure

Abstract Background The nomenclature change from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) better encapsulates the associated metabolic milieu. While MASLD is associated with increased heart failure (HF) risk, characteristics and outcomes of MASLD in patients...

N. Chew, Chandramouli Chanchal, W. Tay et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.